Sunday, July 06, 2025 2:20:35 PM
I'll agree that it's a crime, but at least the UK is considering it. The real crime is that all the regulators can't agree to issue EUA's and permit the EDEN to make the vaccine until they can formally approve it
The vaccine, as I understand it, has no real downside risk, no significant negative side effects. Why shouldn't EUA's be used when such outcomes are seen rather than wasting the years it takes to gain regulatory approvals.
,
This has been going on as long as I know, probably from the day the FDA was formed, and prior to that in countries that predated us.
My point is that the regulators have senses, just like the rest of us, if their senses in observing a trial, speaking to both clinician and patients, and reviewing the top line data says the public should have access to this, why not issue the EUA which would permit it. If they insist, they can have their million pages plus filing, but if all use was reported in a Phase 4, I believe they could fully approve before the paperwork could be developed.
As for the production facilities, that could be a part of Phase 3 inspections and new expansive facilities could be inspected on request so when an EUA was issued, the company was prepared to provide the vaccine or other product.
Gary
The vaccine, as I understand it, has no real downside risk, no significant negative side effects. Why shouldn't EUA's be used when such outcomes are seen rather than wasting the years it takes to gain regulatory approvals.
,
This has been going on as long as I know, probably from the day the FDA was formed, and prior to that in countries that predated us.
My point is that the regulators have senses, just like the rest of us, if their senses in observing a trial, speaking to both clinician and patients, and reviewing the top line data says the public should have access to this, why not issue the EUA which would permit it. If they insist, they can have their million pages plus filing, but if all use was reported in a Phase 4, I believe they could fully approve before the paperwork could be developed.
As for the production facilities, that could be a part of Phase 3 inspections and new expansive facilities could be inspected on request so when an EUA was issued, the company was prepared to provide the vaccine or other product.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
